drugset / Trial / NCT01053507

Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

NCT01053507

Phase 4 Terminated 23 enrolled Cady, Roger, M.D. GlaxoSmithKline · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

This study will evaluate the effectiveness of Treximet when taken for post traumatic headache by measuring any change in the number of headache days or any change in a subject's ability to think following treatment with study medication. Eligible subjects will complete 3 visits. Following Visit 1, subjects will treat with their usual medication and document headache symptoms and therapy in a Headache Diary. After 30 days, subjects will return for Visit 2 and be randomized (like the flip of a coin) to receive Treximet or matching placebo to treat at the same time each day. Treximet will be provided to treat any headache that occurs. Subjects will complete a daily Diary. After 30 days, subjects will exit the study at Visit 3.

Timeline

Start
2010-05
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 500 mg Oral
Comparator Sumatriptan Unknown 85 mg Oral